Who
Jane F. Barlow
Director
Company insider
Files Form 4 as: Director, Sera Prognostics; Director, Viracta Therapeutics; Director, Contrafect; Director, Momenta Pharmaceuticals; Director, TherapeuticsMD.
In numbers
- Trades disclosed
- 28
- Buys
- 1
- Sells
- 0
- Bought
- $9,998
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 17 Apr 2018
- Last trade
- 10 Jul 2026
- Last filed
- 14 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —22,426 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —1,949 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —34,494 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —34,494 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —2,998 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —2,998 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —22,426 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —1,949 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —15,596 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | Viracta Therapeuticsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —10,549 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —7,117 at $0.00 | filing |
| 8 Jun 2023filed 7 Jul 2023 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —63,265 at $0.00 | filing |
| 8 Jun 2023filed 9 Jun 2023 | Viracta Therapeuticsoption or derivative | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 9 Jun 2022filed 10 Jun 2022 | Viracta Therapeuticsoption or derivative | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 17 May 2022filed 18 May 2022 | Contrafectoption or derivative | SEC FORM 4 Code A | $141K42,000 at $3.35 | filing |
| 11 Apr 2022filed 12 Apr 2022 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —140,823 at $0.00 | filing |
| 16 Aug 2021filed 17 Aug 2021 | Viracta Therapeuticsoption or derivative | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 8 Feb 2021filed 11 Feb 2021 | Contrafectoption or derivative | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
News
TherapeuticsMD (NASDAQ:TXMD) vs. Addex Therapeutics (NASDAQ:ADXN) Head to Head ComparisonTXMD · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Jane F. Barlow; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.